Sep 07, 2023 8:01am EDT Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
Sep 05, 2023 8:01am EDT Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 7:01am EDT Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Aug 07, 2023 7:01am EDT Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
Jul 10, 2023 8:00am EDT Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
Jul 05, 2023 4:15pm EDT Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Jun 29, 2023 8:00pm EDT Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Jun 06, 2023 7:35am EDT Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers
Jun 03, 2023 8:00am EDT Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
Dec 08, 2022 7:01am EST Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)
